Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$417,899
in 3 filings, $395K under 10b5-1 plans

Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. LEONARD JOHN M −$395K President and CEO sold 3% of stake
  2. Dube Michael P −$23K VP, Chief Accounting Officer sold 3% of stake

Reading 7 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-06-09 Cohen Fred E Director Grant or award · Stock Option (right to buy) +13,300 13,300
2026-06-09 Bhanji Muna Director Grant or award +9,200 36,403
2026-06-09 Bhanji Muna Director Grant or award · Stock Option (right to buy) +13,300 13,300
2026-03-02 BASTA JAMES EVP, General Counsel Sale −1,211 $13.78 $17K 156,794
2026-03-02 Clark Eliana EVP, Chief Technical Officer Sale −607 $13.78 $8K 93,864
2026-03-01 LEONARD JOHN M President and CEO Grant or award +156,400 1,169,739
2026-03-01 LEONARD JOHN M President and CEO Grant or award · Stock Option (right to buy) +225,400 225,400
2026-03-01 BASTA JAMES EVP, General Counsel Grant or award +46,080 158,005
2026-03-01 BASTA JAMES EVP, General Counsel Grant or award · Stock Option (right to buy) +65,829 65,829
2026-03-01 Lebwohl David EVP, Chief Medical Officer Grant or award +9,943 131,192
2026-03-01 Lebwohl David EVP, Chief Medical Officer Grant or award · Stock Option (right to buy) +14,204 14,204
2026-03-01 Dulac Edward J III EVP, Chief Financial Officer Grant or award +61,280 160,963
2026-03-01 Dulac Edward J III EVP, Chief Financial Officer Grant or award · Stock Option (right to buy) +87,543 87,543
2026-03-01 Schultes Birgit C EVP, Chief Scientific Officer Grant or award +39,200 137,733
2026-03-01 Schultes Birgit C EVP, Chief Scientific Officer Grant or award · Stock Option (right to buy) +56,000 56,000
2026-03-01 Clark Eliana EVP, Chief Technical Officer Grant or award +7,353 94,471
2026-03-01 Clark Eliana EVP, Chief Technical Officer Grant or award · Stock Option (right to buy) +10,505 10,505
2026-03-01 Dube Michael P VP, Chief Accounting Officer Grant or award +17,250 69,527
2026-01-05 LEONARD JOHN M President and CEO Sale −34,146 $9.21 $314K 1,013,339
2026-01-05 Schultes Birgit C EVP, Chief Scientific Officer Sale −8,508 $9.21 $78K 98,533

Page 2 of 40 · 783 trades